Assembly Bio
View On Demand

A Cure For Hepatitis B Is In Clinical Trials

About the Event

The Hepatitis B Virus (HBV) infects 270 million people globally and complications caused by HBV kill close to 1 million people per year.

Given the scope and urgency of the problem, Assembly Bio (NASDAQ: ASMB) has several programs in its pipeline for curing HBV. A triple combo trial is currently in Phase 2 and an a novel oral core inhibitor drug will enter clinical trials later this year.

The Assembly Bio team has over 80 years of experience in treating HCV, HIV, and HBV, andincludes Nobel Laureate, Sir Michael Houghton, PhD as a member of the board of directors.

Join our webinar to hear Assembly Bio President and CEO, Dr. John McHutchison discuss the company’s multi-platform approach to curing HBV and the major inflection points ahead this year and next.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.